GovernanceFDA Weighs Safety Standards for Psychedelic TherapiesBy Riza DagocSep 15, 2026, 4:30 AM UTC
BusinessNovartis M&A Strategy Faces Investor Scrutiny After Drug SetbacksBy Riza DagocSep 11, 2026, 5:43 AM UTC
BusinessNovartis Shares Plunge After Muscle Drug Fails Phase III TrialBy Riza DagocSep 8, 2026, 4:44 PM UTC
HealthSK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug OpakalimBy Riza DagocAug 26, 2026, 5:21 AM UTC
BusinessHanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug DealBy Riza DagocAug 24, 2026, 6:16 AM UTC
BusinessModerna Short Sellers Hit With $4.8 Billion Loss as Stock SoarsBy Riza DagocAug 19, 2026, 9:23 PM UTC